Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2013

01-12-2013 | Original Article

Melatonin Reduces Ulcerative Colitis-Associated Local and Systemic Damage in Mice: Investigation on Possible Mechanisms

Authors: P. P. Trivedi, G. B. Jena

Published in: Digestive Diseases and Sciences | Issue 12/2013

Login to get access

Abstract

Background and Aims

Ulcerative colitis (UC) is a chronic gastrointestinal disorder. Substantial research reveals that melatonin has beneficial effects in ulcerative colitis both experimentally and clinically. We have previously reported that ulcerative colitis was associated with local and systemic damage in mice. The purpose of this study was to reveal the novel targets of melatonin in its protective mechanism against ulcerative colitis in mice. We also wished to determine whether or not melatonin protected against ulcerative colitis-induced systemic damage in mice.

Methods

Ulcerative colitis was induced in mice by use of 3 % (w/v) dextran sulfate sodium for two cycles. One cycle comprised 7 days of DSS-treated water followed by 14 days of normal drinking water. Melatonin was administered at doses of 2, 4, or 8 mg/kg bw/day, po throughout. The effect of melatonin in mice with UC was evaluated by use of biochemical data, histological evaluation, comet and micronucleus assays, immunohistochemistry, and western blot analysis.

Results

The results indicated that melatonin treatment ameliorated the severity of ulcerative colitis by modulating a variety of molecular targets, for example nuclear factor kappa B, cyclooxygenase-2, interleukin 17, signal transducer and activator of transcription 3, nuclear erythroid 2-related factor 2, matrix metalloproteinase-9, and connective tissue growth factor. Further, ulcerative colitis increased gut permeability, plasma lipopolysaccharide level, systemic inflammation, and genotoxicity. Melatonin treatment led to mucosal healing and reduced ulcerative colitis-induced elevated gut permeability and reduced the plasma LPS level, systemic inflammation, and genotoxicity.

Conclusion

Melatonin ameliorated ulcerative colitis-associated local and systemic damage in mice.
Literature
1.
Eijkelkamp N, Heijnen CJ, Lucas A, et al. G protein-coupled receptor kinase 6 controls chronicity and severity of dextran sodium sulphate-induced colitis in mice. Gut. 2007;56:847–854.PubMedCrossRef
2.
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571–583.PubMedCrossRef
3.
Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31:299–306.PubMedCrossRef
4.
Algieri F, Zorrilla P, Rodriguez-Nogales A, et al. Intestinal anti-inflammatory activity of hydroalcoholic extracts of Phlomis purpurea L. and Phlomis lychnitis L. in the trinitrobenzenesulphonic acid model of rat colitis. J Ethnopharmacol. 2013;146:750–759.PubMedCrossRef
5.
Lee MJ, Lee JK, Choi JW, et al. Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS ONE. 2012;7:e38801.PubMedCrossRef
6.
Radema SA, van Deventer SJ, Cerami A. Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. Gastroenterology. 1991;100:1180–1186.PubMed
7.
Trivedi PP, Jena GB. Dextran sulfate sodium-induced ulcerative colitis leads to increased hematopoiesis and induces both local as well as systemic genotoxicity in mice. Mutat Res. 2012;744:172–183.PubMedCrossRef
8.
Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med.. 2009;47:1304–1309.PubMedCrossRef
9.
Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617–629.PubMedCrossRef
10.
Toedter G, Li K, Sague S, et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm Bowel Dis. 2012;18:1399–1410.PubMedCrossRef
11.
Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013;201:19–30.PubMedCrossRef
12.
Gabele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011;55:1391–1399.PubMedCrossRef
13.
Villaran RF, Espinosa-Oliva AM, Sarmiento M, et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease. J Neurochem. 2010;114:1687–1700.PubMedCrossRef
14.
Jena GB, Trivedi PP, Sandala B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res.. 2012;46:1339–1345.PubMedCrossRef
15.
Westbrook AM, Wei B, Braun J, et al. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res. 2009;69:4827–4834.PubMedCrossRef
16.
Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75–78.PubMedCrossRef
17.
Nosal’ova V, Zeman M, Cerna S, et al. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res. 2007;42:364–370.PubMedCrossRef
18.
Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47:2336–2348.PubMedCrossRef
19.
Bonnefont-Rousselot D, Collin F, Jore D, et al. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res. 2011;50:328–335.PubMedCrossRef
20.
Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1–16.PubMedCrossRef
21.
Marchetti C, Sidahmed-Adrar N, Collin F, et al. Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J Pineal Res. 2011;51:286–296.PubMedCrossRef
22.
Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2:181–197.PubMedCrossRef
23.
Gitto E, Tan DX, Reiter RJ, et al. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol. 2001;53:1393–1401.PubMedCrossRef
24.
Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189–200.PubMedCrossRef
25.
Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006;7:423–431.PubMed
26.
Chuang JI, Mohan N, Meltz ML, et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int. 1996;20:687–692.PubMedCrossRef
27.
De Filippis D, Iuvone T, Esposito G, et al. Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res. 2008;44:45–51.PubMed
28.
Mohan N, Sadeghi K, Reiter RJ, et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int. 1995;37:1063–1070.PubMed
29.
Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res. 2001;30:1–12.PubMedCrossRef
30.
Esposito E, Mazzon E, Riccardi L, et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res. 2008;45:166–173.PubMedCrossRef
31.
Mazzon E, Esposito E, Crisafulli C, et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res. 2006;41:363–373.PubMedCrossRef
32.
Tasdemir S, Parlakpinar H, Vardi N, et al. Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid-induced colitis. Fundam Clin Pharmacol. 2013;27:299–307.PubMedCrossRef
33.
Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol. 2011;62:327–334.PubMed
34.
Rakhimova O. Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh. 2010;82:64–68.PubMed
35.
Dong WG, Mei Q, Yu JP, et al. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol. 2003;9:1307–1311.PubMed
36.
Tahan G, Gramignoli R, Marongiu F, et al. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci. 2011;56:715–720.PubMedCrossRef
37.
Akcan A, Kucuk C, Sozuer E, et al. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol. 2008;14:918–924.PubMedCrossRef
38.
Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005;2005:185–193.PubMedCrossRef
39.
Li JH, Zhou W, Liu K, et al. Melatonin reduces the expression of chemokines in rat with trinitrobenzene sulfonic acid-induced colitis. Saudi Med J. 2008;29:1088–1094.PubMed
40.
Necefli A, Tulumoglu B, Giris M, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci. 2006;51:1538–1545.PubMedCrossRef
41.
Mei Q, Xu JM, Xiang L, et al. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J. 2005;81:667–672.PubMedCrossRef
42.
Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin. 2002;23:882–886.PubMed
43.
Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res. 1995;19:31–39.PubMedCrossRef
44.
Motilva V, Garcia-Maurino S, Talero E, et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res. 2011;51:44–60.PubMedCrossRef
45.
Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res. 2010;690:12–23.PubMedCrossRef
46.
Morioka N, Okatani Y, Wakatsuki A. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. J Pineal Res. 1999;27:202–209.PubMedCrossRef
47.
Tripathi A, PremKumar KV, Pandey AN, et al. Melatonin protects against clomiphene citrate-induced generation of hydrogen peroxide and morphological apoptotic changes in rat eggs. Eur J Pharmacol. 2011;667:419–424.PubMedCrossRef
48.
Chava VK, Sirisha K. Melatonin: a novel indolamine in oral health and disease. Int J Dent.. 2012;2012:720185.PubMedCrossRef
49.
Forman K, Vara E, Garcia C, et al. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J Pineal Res. 2010;49:312–320.PubMedCrossRef
50.
Tripathi DN, Jena GB. Effect of melatonin on the expression of Nrf2 and NF-kappaB during cyclophosphamide-induced urinary bladder injury in rat. J Pineal Res. 2010;48:324–331.PubMedCrossRef
51.
Rachmilewitz D, Simon PL, Schwartz LW, et al. Inflammatory mediators of experimental colitis in rats. Gastroenterology. 1989;97:326–337.PubMed
52.
Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.PubMed
53.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.PubMedCrossRef
54.
Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582:67–78.PubMedCrossRef
55.
Dadhania VP, Tripathi DN, Vikram A, et al. Intervention of alpha-lipoic acid ameliorates methotrexate-induced oxidative stress and genotoxicity: a study in rat intestine. Chem Biol Interact. 2010;183:85–97.PubMedCrossRef
56.
Kasamatsu T, Kohda K, Kawazoe Y. Comparison of chemically induced DNA breakage in cellular and subcellular systems using the comet assay. Mutat Res. 1996;369:1–6.PubMedCrossRef
57.
Speit G, Hartmann A. The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 1999;113:203–212.PubMed
58.
Tripathi DN, Pawar AA, Vikram A, et al. Use of the alkaline comet assay for the detection of transplacental genotoxins in newborn mice. Mutat Res. 2008;653:134–139.PubMedCrossRef
59.
Collins AR, Duthie SJ, Dobson VL. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis. 1993;14:1733–1735.PubMedCrossRef
60.
Holden HE, Majeska JB, Studwell D. A direct comparison of mouse and rat bone marrow and blood as target tissues in the micronucleus assay. Mutat Res. 1997;391:87–89.PubMedCrossRef
61.
Tanaka T, Yasui Y, Tanaka M, et al. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact. 2009;177:128–136.PubMedCrossRef
62.
Awney HA, Attih AM, Habib SL, et al. Effect of melatonin on the production of microsomal hydrogen peroxide and cytochrome P-450 content in rat treated with aflatoxin B(1). Toxicology. 2002;172:143–148.PubMedCrossRef
63.
Costantino G, Cuzzocrea S, Mazzon E, et al. Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. Eur J Pharmacol. 1998;363:57–63.PubMedCrossRef
64.
Huang F, Ning H, Xin QQ, et al. Melatonin pretreatment attenuates 2-bromopropane-induced testicular toxicity in rats. Toxicology. 2009;256:75–82.PubMedCrossRef
65.
Okatani Y, Wakatsuki A, Reiter RJ, et al. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol. 2003;469:145–152.PubMedCrossRef
66.
Patel V, Upaganlawar A, Zalawadia R, et al. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010;644:160–168.PubMedCrossRef
67.
Subramanian P, Mirunalini S, Pandi-Perumal SR, et al. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol. 2007;571:116–119.PubMedCrossRef
68.
Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y).. 2012;8:29–38.
69.
Swarnakar S, Mishra A, Ganguly K, et al. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res. 2007;43:56–64.PubMedCrossRef
70.
Ganguly K, Swarnakar S. Induction of matrix metalloproteinase-9 and -3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J Pineal Res. 2009;47:43–55.PubMedCrossRef
71.
Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49:271–282.PubMedCrossRef
72.
Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNA damage in the rat kidney. Toxicology. 1999;139:81–91.PubMedCrossRef
73.
Westbrook AM, Wei B, Hacke K, et al. The role of tumour necrosis factor-alpha and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity. Mutagenesis. 2012;27:77–86.PubMedCrossRef
74.
Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–123.PubMedCrossRef
75.
Li Volti G, Musumeci T, Pignatello R, et al. Antioxidant potential of different melatonin-loaded nanomedicines in an experimental model of sepsis. Exp Biol Med (Maywood). 2012; 237:670–677.
Metadata
Title
Melatonin Reduces Ulcerative Colitis-Associated Local and Systemic Damage in Mice: Investigation on Possible Mechanisms
Authors
P. P. Trivedi
G. B. Jena
Publication date
01-12-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2831-6

Other articles of this Issue 12/2013

Digestive Diseases and Sciences 12/2013 Go to the issue

Original Article

Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

Original Article

Hypoxia-Induced Snail Expression Through Transcriptional Regulation by HIF-1α in Pancreatic Cancer Cells

Original Article

Lack of Impact on Polyp Detection by Fellow Involvement During Colonoscopy: A Meta-Analysis

Stanford Multidisciplinary Seminars

Infliximab for the Treatment of Granulomatous Peritonitis

Review

Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature

Correspondence

Mesenchymal Stem Cells and Granulomas in Crohn’s Disease and Intestinal Tuberculosis: The Way Forward

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits